Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597183 | 1.00 | GPR119 (0.45) | GPR119KCNH2FPR2NR1H2CYP3A4 | |
| SCHEMBL12185779 | 0.91 | GPR119 (0.51) | GPR119KCNH2NR1H2CYP3A4 | |
| SCHEMBL15023318 | 0.91 | GPR119 (0.51) | GPR119KCNH2NR1H2CYP3A4 | |
| SCHEMBL15022719 | 0.90 | GPR119 (0.45) | GPR119KCNH2CYP3A4TIPARP | |
| SCHEMBL12185775 | 0.90 | GPR119 (0.55) | GPR119 | |
| SCHEMBL2597412 | 0.90 | GPR119 (0.45) | GPR119KCNH2CYP3A4TIPARP | |
| SCHEMBL15047765 | 0.90 | GPR119 (0.44) | GPR119KCNH2NR1H2CYP3A4TIPARP | |
| SCHEMBL15023397 | 0.90 | GPR119 (0.55) | GPR119 | |
| SCHEMBL12185791 | 0.89 | GPR119 (0.45) | GPR119KCNH2CYP3A4 | |
| SCHEMBL15023779 | 0.89 | GPR119 (0.45) | GPR119KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | GPR119 1/4885KCNH2 1430/4885FPR2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.